

# PRIOR AUTHORIZATION CRITERIA

<b>DRUG CLASS</b>	<b>DRONABINOL PRODUCTS</b>
<b>BRAND NAME (generic)</b>	<b>MARINOL (dronabinol)</b>
	<b>SYNDROS (dronabinol oral solution)</b>
<b>Status: CVS Caremark Criteria</b>	
<b>Type: Post Limit Prior Authorization</b>	

## POLICY

### FDA-APPROVED INDICATIONS

Marinol and Syndros are indicated in adults for the treatment of:

- anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS).
- nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for nausea and vomiting associated with cancer chemotherapy  
**AND**
- The patient has failed to respond adequately to a conventional antiemetic treatment  
[Note: Examples of conventional antiemetic treatments include dexamethasone, metoclopramide, olanzapine, prochlorperazine, and 5-HT3 receptor antagonists (e.g., Anzemet [dolasetron], granisetron, ondansetron)]

Quantity Limits apply.

<u>POST LIMIT QUANTITY</u>		
<b>Drug</b>	<b>1 Month Limit*</b>	<b>3 Month Limit*</b>
Marinol 2.5 mg, 5 mg, 10 mg (dronabinol capsules)	120 capsules / 25 days	360 capsules / 75 days
Syndros (dronabinol oral solution)	240 mL / 25 days	720 mL / 75 days

\*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

### REFERENCES

1. Marinol [package insert]. Parsippany, NJ: ThePharmaNetwork LLC; August 2017.
2. Syndros [package insert]. Chandler, AZ: Insys Therapeutics, Inc.; September 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed January 2021.
4. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed January 2021.

5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Antiemesis. V. 1.2021. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/antiemesis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf). Accessed January 2021.
6. Hesketh P, Kris M, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2017;35:3240-61.
7. American Society of Clinical Oncology. Understanding Chemotherapy. <https://www.cancer.net/navigating-cancer-care/how-cancer-treated/chemotherapy/understanding-chemotherapy>. May 2019. Accessed January 2021.
8. American Cancer Society. How is Chemotherapy Used to Treat Cancer? <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html>. November 2019. Accessed January 2021.